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ABSTRACT 
Objective: The present study was aimed to alter the pharmacokinetic parameters of the drug pentoxifylline using a novel natural mucoadhesive 
polymer from two different plants, Manilkara zapotta Linn and Ocimum basilicum Linn.  
Methods: The polymer was isolated and six batches of mucoadhesive tablets of pentoxifylline was formulated with 3 different concentrations of 
each polymer. The best formulation from each of the polymer was selected and administered to rabbits and the plasma drug concentration was 
compared with the marketed formulation. The pharmacokinetic parameters such as such as Cmax, tmax , AUC, AUMC, λz, t1/2
Results: The plasma drug concentration vs time curve shows the extended-release of pentoxifylline when compared with the conventional 
marketed formulation. The results show that there is no change in the peak plasma concentration, but the significant difference was observed in t
, and MRT were 
determined.  
½, 
Conclusion: The isolated polymer from the plants Manilkara zapotta Linn. and Ocimum basilicum Linn can be used as a carrier for developing 
mucoadhesive formulations and it alter the pharmacokinetic of pentoxifylline positively. 
which showed approximately 2.5 fold increase from 2.44 to 6.87 h and the AUC showed five-fold increase from 22.40 to 117.19 μg*h/ml, and other 
pharmacokinetic parameters, when compared with the marketed formulation.  
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Recently the mucoadhesive drug delivery systems have gained more 
attention in the pharma profession [1]. Mucoadhesion is a converse 
of bioadhesion, which is aimed to localize the drugs in the mucosal 
area of the body. The water-soluble polymers were used for the 
formulation of mucoadhesive drug delivery systems because they 
become adhesive during hydration. The mucoadhesive drug delivery 
systems are aimed to target the drug with increased gastric 
residence time, bioavailability, minimized the first-pass effect, 
controlled release of the drug with reduced adverse effects [2, 3]. 
The mucoadhesive polymers selected should be non-toxic, non-
irritant, non-absorbable, non-covalent, biocompatible, adhesive and 
economic, in nature [4]. Either natural (gelatin, guar gum and 
sodium alginate) or synthetic/semi-synthetic (Hydroxypropyl 
methylcellulose, Carbopol 934 and Sodium carboxy methyl 
cellulose), may be used alone or in a combination of two or more for 
the mucoadhesive drug delivery systems [5-9]. 
Pentoxifylline (PTX) (1-[5-oxohexyl]-3,7-dimethylxantine), an orally 
active hemorheological drug, which is used for the treatment of 
intermittent claudication or other circulatory disorders. Its 
hemorheological effect involves by reducing the blood viscosity and 
increasing the erythrocyte deformability [10]. PTX is a highly water-
soluble drug (~77 mg/ml). It is well absorbed from the 
gastrointestinal tract (>95 %), yet the actual amount of drug 
bioavailable to the body is only about 20 % because of its extensive 
hepatic first-pass metabolism. Administration of a single dose of 
extended-release tablets of PTX(400 mg) resulted in a Cmax of 55-
300 ng/ml and tmax
Manilkara zapota Linn. (MZL), is an evergreen plant belongs to the 
family Sapotaceae, grows up to 8-15 m height. It is cultivated 
throughout the Indian subcontinent including Bangladesh, though it 
is native to Mexico and Central America. The seeds of MZL are 
diuretic tonic aperients and febrifuge. The stem bark acts as an 
astringent, febrifuge [12] and anticancer [13]. The leaves and bark 
are used to treat cough, cold, dysentery and diarrhea [14]. 
Antimicrobial and antioxidant activities are also reported from the 
leaves of MZL [15, 16]. A natural gum from the seeds of the plant 
was also isolated [17]. 
 values of 2-4 h [11]. Since PTX has a short 
biological half-life (about 0.4-0.8 h), the frequent dosing is necessary 
to maintain the therapeutic plasma drug concentration. 
Ocimum basilicum Linn. (OBL) is an erect, almost glabrous herb, 
belonging to the Lamiaceae family, native to Iran, Afghanistan, and 
India, which grows to between 30 and 90 cm high. The leaves are 
ovate, lanceolate, cucuminate, toothed or entire, glabrous on both 
surfaces and glandular. When mature, they reach approximately 5 
cm in length, excluding the petiole, which is approximately 2 cm 
long. The upper surface is smooth and lustrous; on the lower surface 
along the midrib and the petiole short, stiff hairs occur sparingly 
[18]. It represents an important source of essential oil used in food, 
pharmaceutical, perfumery, and cosmetics industries [19]. Its 
aromatic leaves are used in fresh or dried forms as a drug in 
traditional medicine and as a flavoring agent in food and 
confectionery products as well as beverages [18, 20]. The seeds of 
OBL 
Even though several kinds of research have been made in the area of 
alteration of pharmacokinetic parameters, mucoadhesive drug 
delivery systems based on plant-derived polymers also plays a vital 
role due to their emollient, lack of toxicity, and low cost. In vitro 
experiments have previously reported that the mucoadhesive 
polymers of MZL [22] and OBL [23] were suitable agents for the 
preparation of a controlled release tablet formulation of PTX. So, in 
this present work, an attempt was made to investigate the effect of 
these two natural mucoadhesive polymers in the alteration of 
pharmacokinetic parameters of the PTX.  
are high in fiber (22.6%) and some regions of Asia like Iran and 
India, basil seeds are frequently included in beverages and desserts 
for aesthetic purposes as well as a source of dietary fiber [21]. 
The seeds of MZL and OBL were purchased from the local vendors of 
Chennai, Tamilnadu in February 2018. The collected seeds were 
identified and authenticated by a botanist Dr. S. Balasubramanian, 
ABS Medicinal garden, Salem. The voucher specimens (MZG-1 and 
OBG-1) were kept in our museum for future reference. Pentoxifylline 
was obtained as a gift sample from Shasun Pharmaceuticals, 
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Puducherry. Microcrystalline cellulose and magnesium stearate 
were purchased from Central Drug House (India). Acetone, diethyl 
ether, and petroleum ether were from Qualigens (India) and sodium 
hydroxide from E-Merck (India). All the chemicals used were of 
analytical grade 
Three batches of mucoadhesive polymers of Manilkara zapotta Linn. 
(MAPMZ) and Ocimum basilicum Linn. (MAPOB) were prepared on a 
laboratory scale by the method of Rao et al. [24]. 20 g of the seed 
powders were mixed individually with 200 ml of cold distilled water 
and the slurry was prepared. Then 800 ml of boiling water was 
added to the slurry and boiled for another 20 min with continuous 
stirring. The solutions were kept overnight to settle the solid matter. 
The clear solutions were centrifuged for 20 min at 5000 rpm. The 
supernatant fluids were separated and twice the volume of acetone 
was added with continuous stirring. The formed precipitates were 
filtered and washed with petroleum ether and diethyl ether and then 
dried under vacuum at 50-60 ° C. The dried materials were sieved 
through sieve No 80 and used for the formulation of tablets.  
The mucoadhesive tablets of pentoxifylline (MATP) were prepared by 
using direct compression technique. Pentoxifylline, mucoadhesive 
polymer, microcrystalline cellulose, magnesium stearate were 
accurately weighed, mixed/uniformly and this mixture was 
compressed into tablets by using Elite multi-station punching machine 
(Erweka) with 10 mm flat punches. The compression force was 
adjusted to give tablet hardness in the range of 7 to 11 kp. The 
constituent of the formulation is presented in table 1. 
 
Table 1: Formulation of mucoadhesive tablets of pentoxifylline 
Ingredients F1 F2 F3 F4 F5 F6 
Pentoxifylline 400 400 400 400 400 400 
Microcrystalline cellulose 152 122 92 152 122 92 
MAPMZ 30 60 90 - - - 
MAPOB - - - 30 60 90 
Magnesium stearate 18 18 18 18 18 18 
Total weight (mg) 600 600 600 600 600 600 
All the quantities are in mg 
 
Female New Zealand white rabbits
The rabbits were administered with the respective formulations along 
with 100 ml of water. The blood samples were collected into heparinized 
vacuum tubes at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 20 and 24 h following 
the PTX administration. After collection, the blood samples were 
centrifuged at 1000 rpm for 10 min at room temperature (25 ° C); 
followed by direct transfer into microcentrifuge tubes and stored at–70 ° 
C until analysis. The amount of food and water intake for each animal 
was standardized during the sampling day.  
 of either sex or approximately 
the same age, weighing about 1.5 to 1.6 kg, procured from Sri 
Venkateswara Enterprises, Bengaluru (Reg No. 237/99), were used 
for the study. They were housed in separate metallic cages and fed 
with standard chow diet and water ad libitum. The animals were 
exposed to an alternate cycle of 12 h of darkness and light each. 
Before each test, the animals fasted for at least 12 h. The 
experimental protocols were subjected to the scrutinization of the 
Institutional Animal Ethics Committee and were cleared by the same 
(Approval No. P. COL/20/2019/IAEC/VMCP). The animals were 
divided into 3 groups each consisting of three. The first group was 
administered with marketed pentoxifylline tablets 400 mg and the 
second group treated with the mucoadhesive tablets formulated 
with MAPMZ (F3) and the third group treated with the 
mucoadhesive tablets formulated with MAPOB.  
A stock solution of PTX (40 μg/ml) was prepared by dissolving in 
double-distilled water. The working standard solutions of PTX were 
produced by diluting the stock solutions with blank rabbit plasma 
(1:1). The ten calibration standards of PTX were prepared 
independently. The concentration range of PTX was 10 to 2000 ng/ml. 
All stock solutions, stored at 4 ° C, were stable for at least one month 
without any degradation. The liquid-liquid extraction method was 
used for the sample preparation of PTX. 0.1 ml of 1 M sodium 
hydroxide and 7 ml of dichloromethane were added to 1 ml of plasma. 
The mixture was vortexed for 30 sec and centrifuged at 3000 rpm for 
15 min. The upper layer was removed and the organic phase was 
placed into another test tube and evaporated to dryness under a flow 
of nitrogen stream at 37 °C. The residue was redissolved in 0.2 ml of 
the mobile phase (acetonitrile: water, 28:72, v/v) and 30 μl of this 
solution was injected directly on to the column. The plasma extract 
was stable for at least two days when kept at 4 °C. 
The PTX concentrations in plasma were assayed using a validated 
high performance liquid chromatography with ultraviolet detection 
(UV-HPLC) [25, 26]. A high-performance liquid chromatograph 
(Hewlett-Packard Series 1050) was equipped with a variable 
wavelength UV detector. The analytical column was a reverse phase, 
300 x 3.9 mm I.D., RP-18 μm Hyperbond (Hypersil). The detection 
was at 274 nm. The mobile phase was a combination of acetonitrile: 
water (28:72, v/v) and the flow rate was 1 ml/min. The retention 
time of PTX was 5.15 min (retention volume 5.15 ml). The 
bioanalytical method was specific with no interfering impurities at 
the retention time of PTX. The linear calibration model was 
constructed between peak-height and concentration of PTX in 
plasma samples.  
The method exhibited a linearity of response over a range of 10-
2000 ng/ml for PTX (r2=0.998). Limit of detection and limit of 
quantification were found to be 5 and 10 ng/ml, respectively. 
Quality control samples at three levels, low (30 ng/ml), middle (600 
ng/ml) and high (1600 ng/ml) for PTX were used during routine 
analysis. The within-batch precision ranged from 2.30 to 5.35 % and 
accuracy ranged from 99.6 to 103 %. The between-batch precision 
and accuracy ranged from 4.43 to 6.85 and 102 to 105 %, 
respectively. The stability of the samples under frozen conditions, at 
room temperature, and during the freeze-thaw cycle was also 
determined. The accuracy and precision for calibration curve 
standards and quality samples in all bioanalytical methods met the 
acceptance criteria as per FDA guidelines. 
Pharmacokinetic evaluation non-compartmental modeling was used 
to estimate PTX pharmacokinetic parameters after single-dose 
administration. The PTX plasma concentration vs time data were 
evaluated by using PKSolver. Pharmacokinetic parameters such as 
maximum PTX concentration (Cmax) in plasma, the time that Cmax 
occurred (tmax), area under the plasma concentration time curve 
from 0 to 24 h (AUC0-24) and 0 to infinity (AUC0-∞), elimination rate 
constant (λz), biological half-life (t1/2
The area under the plasma concentration versus time curve from 0 
to 24 h (AUC
), Apparent volume of 
distribution during terminal phase after non-intravenous 
administration (Vz/F), Apparent total clearance of the drug from 
plasma after oral administration (Cl/F) and mean residence time 
(MRT) were determined.  
0-24) was assessed using the linear trapezoidal 
methodology and was extrapolated to infinity (AUC0-∞). The 
maximum plasma concentration (Cmax) and time to reach Cmax (tmax) 
for PTX were directly obtained from the individual observed data. 
The terminal phase elimination rate (λz) was estimated using a log-
linear regression of the observed plasma concentration point in the 
terminal phase, and the elimination half-life (t1/2) was calculated as 
0.693/λz. The apparent total clearance (Cl/F) and volume of 
distribution (Vz/F) were calculated using the formulas dose/AUC0-∞ 
and dose/(λz *AUC0-∞), respectively. 
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Each experiment was repeated at least three times. The results are 
expressed as the mean±SD One-way analysis of variance was used to 
test the statistical significance of differences among groups. 
Statistical significance of the differences of the means was 
determined by Student’s t-test. 
Pentoxifylline is a synthetic dimethyl xanthine derivative prescribed 
for complications of peripheral vascular diseases. Although 
pentoxifylline is almost completely absorbed, it undergoes 
significant first-pass metabolism resulting in a bioavailability of 20% 
and frequent dosing is necessary [27]. Mucoadhesive drug delivery 
systems are used to increase the bioavailability of drugs. Natural 
polymers are preferred over synthetic and semi-synthetic polymers 
due to their low cost, non-toxic, emollient, free availability and non-
irritating nature [28-30]. Even though many polymers are available, 
a search for new polymers still interesting to get more efficacious 
polymers with less toxic. So in this present work, an attempt was 
made to study the effect of mucoadhesive polymers in the 
modification of pharmacokinetic properties of PTX. 
The mucilage was isolated from the seeds of M. zapota and O. 
basilicum by the method of Rao et al. [24]. The mucoadhesive tablets 
of pentoxifylline were formulated by using three different 
concentrations of MAPMZ and MAPOB at 5, 10 and 15 %. Six 
formulations of F1 to F6 were formulated and evaluated for the 
mucoadhesive property and in vitro release. From the earlier studies 
[22, 23] it was proved that the tablets formulated with the polymers 
showed good mucoadhesive strength in rabbit buccal mucosa. One 
best formulation from each of the polymers was selected for the 
pharmacokinetic studies. Formulation F3 showed the release of 
99.44 % of cumulative release and the formulation F6 showed 99.84 
% release at 12 and 10 h respectively. So these two formulations (F3 
and F6) were selected for the pharmacokinetic studies in rabbits. 
Female New Zealand white rabbits of either and the same age
  
, 
weighing about 1.5 to 1.6 kg were used for the study. The 
formulations F3, F6, and marketed formulation were administered 
to rabbits along with 100 ml of water. The drug concentrations in 
plasma after the administration PTX in 3 groups were followed for 
24 h. The PTX concentrations in plasma were assayed using a 
validated high-performance liquid chromatography with the UV-
HPLC method. The mean plasma concentration versus time profiles 
for PTX after a single oral dose of PTX is shown in fig. 1. The 
pharmacokinetic parameters were calculated by using PKSolver. The 
results are given in table 2. 
 
Fig. 1: Mean plasma concentration of PTX after a single oral dose (mean±SD; n=3) 
 
Table 2: Non-compartmental extravascular pharmacokinetic parameters after single-dose administration of PTX on rabbits 
Parameters Values 
F3 F6 Marketed formulation 
λz (h-1 0.1187388 ) 0.1008491 0.2838929 
t1/2 5.8375792  (h) 6.8731144 2.4415796 
Tmax 4  (h) 4 1 
Cmax 8.351333  (μg/ml) 8.212667 8.499333 
AUC0-t 117.18833  (μg*h/ml) 107.31067 22.408331 
AUC0-∞ 128.27148  (μg*h/ml) 118.14864 22.440033 
AUMC0-∞  (μg*h2 1460.5715 /ml) 1370.4631 65.788487 
MRT (h) 11.386565 11.599482 2.9317465 
Vz/F (L) 26.262569 33.57062 62.788764 
Cl/F (L/h) 3.118386 3.3855657 17.825286 
(All values are calculated from the mean of Plasma PTX concentration; n=3) 
 
The absorption of PTX is rapid in marketed formulation than the test 
formulations; the mean tmax of the marketed formulation was 1 h, 
while in the formulation F3 and F6, the mean tmax was around 4 h. 
This shows that the mucoadhesive tablets formulated with MZL and 
OBL were effective in delaying the peak plasma concentration of 
PTX. The peak plasma concentrations (Cmax) of PTX were found to be 
8.35, 8.21 and 8.50 μg/ml, respectively for the F3, F6, and marketed 
formulation. It indicates there is no significant change in the peak 
plasma concentration when it is given as controlled release 
formulation or a conventional marketed release formulation, which 
assures the formulations F3, and F6 are in the same therapeutic 
window of the marketed formulation. The Kel values were found to 
be 0.119, 0.101 and 0.284 h-1calculated from the slope of the plasma 
concentration-time data. A decrease in elimination rate constant of 
formulations F3 and F6 indicated the slow/sustained release of the 
drug PTX in rabbit [31]. 
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AUC0-∞ in plasma were 128.271, 118.149 and 22.440 μg. h/ml, 
respectively, for the formulations F3, F6 and marketed formulation, 
which indicated the increased bioavailability of the mucoadhesive 
formulation. The AUC of the formulation F3 and F6 was increased 
almost 5-6 fold, which shows the sustained release of the drug PTX 
for an extended period. The elimination rate of PTX was relatively 
fast with a t1/2 of 5.84, 6.87 and 2.44 h. The t1/2 values were found to 
vary widely; similar results were reported by Beerman et al., [11] 
who obtained a mean t1/2
PTX is hepatically metabolized by hydroxylation and demethylation 
to six renally excreted metabolites [32]. The presence of a high 
concentration of PTX may alter the mechanism of metabolizing 
enzymes by saturation, which may lead to increased bioavailability. 
On the other hand, PTX is reduced extrahepatically to form an 
intermediate metabolite known as hydroxy-PTX which may be 
converted back to the parent compound or possibly be metabolized 
further [33]. Pentoxifylline has a wider therapeutic range (1200-
2000 mg/day) in humans for oral application [34]. In this present 
study, each animal was administered with 400 mg of PTX either 
formulated with MZL or OBL and the marketed formulation for the 
evaluation of bioavailability and other pharmacokinetic parameters. 
 value of 3.43 h. The other parameters like 
AUMC also found to be higher in the F3 and F6 formulations. The 
controlled release characteristics of the formulated mucoadhesive 
tablets were reflected in the MRT. The MRT was noticeably 
increased following oral administration of the PTX mucoadhesive 
formulations (11.387, 11.599 h) as compared to the conventional 
marketed formulation (2.93 h).  
The significant difference was observed in all the pharmacokinetic 
parameters between both the formulations with the marketed 
formulation. Thus, the results of the present study clearly indicated 
the applicability of mucoadhesive polymer in the alteration of 
pharmacokinetic parameters of the drug PTX. We concluded that 
enhancement in the bioavailability of PTX would suggest that 
mucoadhesive tablet formulation could be used to improve the oral 
bioavailability of PTX.  
The pharmacokinetic study of the formulated mucoadhesive tablets 
of PTX in rabbits was carried out in view of the alteration of the 
pharmacokinetic parameters. The tablets were formulated with the 
mucoadhesive polymers MZL and OBL. The plasma drug 
concentration versus time interval was estimated by UV-HPLC. The 
increase in tmax value and decrease in Cmax
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